Daiichi Sankyo

vorige Seite Seite 1 von 1 nächste Seite

Daiichi Sankyo Announces the Presentation of New Data on LIXIANA® (edoxaban) to be Presented at ESC Congress 2019

Daiichi Sankyo Europe GmbH (hereafter, Daiichi Sankyo) today announced clinical results for edoxaban (known by the brand name LIXIANA®) will be featured as a late-breaking oral presentation and as poster …

22.08.2019 09:00

Bempedoic Acid CLEAR Serenity Study Results Published in the JAHA Demonstrated Significant LDL-Cholesterol Lowering and Reduced hsCRP in Statin Intolerant Patients

Daiichi Sankyo Europe GMbH (hereafter, 'Daiichi Sankyo') and Esperion Therapeutics (NASDAQ: ESPR) announced today that results from the 345 patient, 24-week, Phase 3 double-blind, placebo-controlled study …

02.04.2019 13:44

Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer

Daiichi Sankyo announces the initiation of Hokusai-VTE Cancer, a multinational study investigating edoxaban in venous thromboembolism (VTE) associated with cancer

18.06.2015 14:03

European Survey Highlights the Risk to Patients Caused by Inconsistency in Hypertension Management

For distribution to the consumer and medical media across Europe (excluding the UK)

08.07.2011 08:04

Global Phase III Trial With Selective c-MET Inhibitor Tivantinib (ARQ 197) Starts Enrolling Patients in Europe

Daiichi Sankyo announced today that it has begun enrolling patients in Europe into a large, multinational phase III trial of tivantinib (ARQ 197).

18.04.2011 08:04
12.01.2011 16:05

Daiichi Sankyo Announces First European Approval for Sevikar HCT(R), a New Three-in-one Combination Product for the Treatment of High Blood Pressure*

Daiichi Sankyo Europe announced today that Sevikar HCT(R) is now approved in Germany, the first market to launch this new once-daily three-in-one combination product for the treatment of high blood pressure …

20.12.2010 10:06

Patients with Hypertension at Risk Due to Physician Inertia

Data announced for the first time at ESH suggest that patients with hypertension are at increased cardiovascular risk due to clinician inertia, because physicians are failing to treat targets set by …

21.06.2010 15:33

Daiichi Sankyo Submits First New Drug Application for Oral Factor Xa Inhibitor, Edoxaban

Daiichi Sankyo Company, Limited announced today that it has submitted a New Drug Application to the Ministry of Health, Labor and Welfare in Japan seeking approval of the anticoagulant, edoxaban, for the …

06.04.2010 12:52

HOKUSAI VTE - Largest Single Phase III Trial for the Treatment and Prevention of Recurrent VTE Started in Europe

Edoxaban, a direct oral factor Xa inhibitor, is now being investigated in a second large-scale pivotal phase III trial, HOKUSAI (pronounced hoek-sigh) VTE.

26.02.2010 11:03
07.12.2008 18:38

Daiichi Sankyo lädt ein: Eine unerzählte Geschichte über Bluthochdruck...die Herausforderung fürs Leben

- Eine Medienveranstaltung bietet Einblick in das Thema Bluthochdruck und seine Herausforderungen

10.06.2008 21:55
vorige Seite nächste Seite